Shire CFO to exit in wake of failed AbbVie deal

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Shire CFO to exit in wake of failed AbbVie deal

Shire's interim chief financial officer, James Bowling, is quitting his current role and moving to the same position at Severn Trent, the London Evening Standard reports. The company ($SHPG) said it would kick off its search for a new CFO "immediately." The news comes at a transitional moment for Shire, as the company is still reeling from its failed deal with Illinois-based AbbVie ($ABBV). Last week, AbbVie said it would recommend that shareholders vote against the proposed merger, responding to new guidelines that make it more difficult for companies to shift their domicile abroad for tax-paying purposes. Story

Shire
James Bowling will step down as CFO.


GlaxoSmithKline
Moncef Slaoui will head the vaccines unit.

Pharma

GlaxoSmithKline ($GSK) R&D chief Moncef Slaoui will shift over to chair the vaccines unit--soon to be bolstered by a $7.1 buyout of most of Novartis' ($NVS) vaccines portfolio--effective immediately. Article

Amgen ($AMGN) appointed R. Sanders Williams to its board of directors. Release

> Raptor Pharmaceutical ($RPTP) has appointed David Happel as chief commercial officer and Kimberly Lee as vice president of corporate strategy and communications. Release

Biotech

> Cubist Pharmaceuticals ($CBST) CEO Michael Bonney stepped down and the company's COO and president, Robert Perez, will take his place. More

> Biogen Idec ($BIIB) brought on two neuroscientists: Christopher Henderson as vice president of neurology and Dr. Richard Ransohoff as a senior research fellow in neuroimmunology. Release

> Therapix named Jan Turek as its new CEO. Release

> BaseHealth tapped former Illumina ($ILMN) executive Jorge Velarde to be its new CEO and president. Release

> Aesica appointed Detlef Behrens to be the company's vice president of business development and Sven Wrabletz to be its business development director. Release

> LeRoux Jooste joined Advanced Cell Technology ($ACTC) as the company's senior vice president of business development and chief commercial officer. Release

> Revalesio named Bert van den Bergh as president. Release

> Zola Horovitz will retire from GenVec's ($GNVC) board of directors. Release

> Epic Sciences named Michael Giske as its chief information officer. Release

Advaxis ($ADXS) appointed Dr. David Mauro as its chief medical officer. Release

> Karus Therapeutics named Simon Roitt as its head of clinical development and Peter Finan as its head of biology. Release

> Cytori Therapeutics ($CYTX) announced that Lloyd Dean would resign from the board of directors. Release

> David Badour joined Apollo Medical Holdings as its senior vice president of business development. Release

> RRD International hired Brian Gallagher as its senior vice president and chief financial officer. Release

> TrialScope appointed Richard Aguinaldo as its chief financial officer. Release

> Otonomy ($OTIC) appointed Anthony Yost as its chief commercial officer. Release

> ProNAi Therapeutics has added 5 new executives to its senior management team: Dr. Angie You as chief business and strategy officer and head of commercial; Wendy Chapman as senior vice president, clinical operations; Chandra Lovejoy, senior vice president of global regulatory affairs and quality; Emma McCann, vice president, program management; and James Smith, vice president, corporate affairs. Release

> John McKew has joined aTyr Pharma as vice president of research. Release

> Eleven Biotherapeutics ($EBIO) has appointed Wendy Dixon to its board of directors. Release

> Metabolic Solutions Development has appointed Dr. Robert Zerbe to its board of managers. Release

> Cardio3 BioSciences has appointed Dr. Warren Sherman as its chief medical officer. Release

> Dr. Carole Ben-Maimon has resigned as president of global pharmaceuticals at Impax Laboratories ($IPXL). Release

> AbVitro has appointed Jeffrey Ostrove as CEO. Release

Diagnostics

> 23andMe appointed Ruby Gadelrab as its vice president of commercial marketing. Release

 

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.